| 冯燕茹,刘鲁迎,朱远.中性粒细胞与白蛋白比值预测病理Ⅱ/Ⅲ期直肠癌术后辅助放化疗急性不良反应和生存[J].中华放射医学与防护杂志,2019,39(9):663-667.Feng Yanru,Liu Luying,Zhu Yuan.Associations of neutrophil to albumin ratio with acute adverse events and survival in patients with pathological stage Ⅱ/Ⅲ rectal cancer receiving adjuvant chemoradiotherapy[J].Chin J Radiol Med Prot,2019,39(9):663-667 |
| 中性粒细胞与白蛋白比值预测病理Ⅱ/Ⅲ期直肠癌术后辅助放化疗急性不良反应和生存 |
| Associations of neutrophil to albumin ratio with acute adverse events and survival in patients with pathological stage Ⅱ/Ⅲ rectal cancer receiving adjuvant chemoradiotherapy |
| 投稿时间：2019-07-05 |
| DOI：10.3760/cma.j.issn.0254-5098.2019.09.005 |
| 中文关键词: 直肠癌 中性粒细胞/白蛋白比值 放化疗 急性不良反应 生存率 |
| 英文关键词:Rectal cancer Neutrophil to albumin ratio Chemoradiotherapy Acute adverse event Survival |
| 基金项目:河南省科技计划项目（182102310578） |
|
| 摘要点击次数: 3683 |
| 全文下载次数: 1710 |
| 中文摘要: |
| 目的 探讨辅助放化疗前外周血细胞为基础的炎症标志物与病理Ⅱ/Ⅲ期直肠癌术后辅助放化疗急性不良反应和生存的关系。方法 本研究共纳入109名直肠癌患者。用受试者工作特征（ROC）曲线计算中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）、淋巴细胞与单核细胞比值（LMR）和中性粒细胞与白蛋白比值（NAR）对总生存率（OS）的预测能力。结果 NAR与2级以上白细胞减少症的发生有关（OR=4.442，95%CI：1.216~16.221，P<0.05）。NAR ≥ 0.055和NAR<0.055患者的5年总生存率分别为68.2%和83.9%（P>0.05），5年无瘤生存率分别为59.1%和76.8%（χ2=3.887，P<0.05）。Cox比例风险模型的多变量分析显示，NAR与OS显著相关（HR=3.035，95%CI：1.021~9.019，P<0.05）。结论 辅助放化疗前NAR可作为直肠癌术后辅助放化疗急性不良反应和预后的生物标志物。 |
| 英文摘要: |
| Objective To evaluate whether any association exists between peripheral blood cell-based inflammatory biomarkers obtained before adjuvant chemoradiotherapy and adverse events (AEs) and survival of patients with pathological stage Ⅱ/Ⅲ rectal cancer treated by adjuvant chemoradiotherapy. Methods A total of 109 rectal cancer patients were included. The prognostic abilities of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR) and neutrophil to albumin ratio (NAR) for overall survival (OS) were calculated by the receiver operating characteristic (ROC) curves. Results NAR was associated with the occurrence of grade ≥ 2 leukopenia (OR=4.442, 95% CI:1.216-16.221, P<0.05). The 5-year OS rates of patients with NAR ≥ 0.055 and patients with NAR<0.055 were 68.2% and 83.9%, respectively (P>0.05). The 5-year disease-free survival (DFS) rates of patients with NAR ≥ 0.055 and patients with NAR<0.055 were 59.1% and 76.8%, respectively (χ2=3.887, P<0.05). Multivariate analysis by Cox proportional-hazards model showed that NAR was significantly associated with OS (HR=3.035, 95% CI:1.021-9.019, P<0.05). Conclusions These results suggest that NAR obtained before adjuvant chemoradiotherapy might serve as an independent biomarker for predicting AEs and prognosis in rectal cancer treated with adjuvant chemoradiotherapy. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |